Last 47 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.87 | — | — | — | — | — | — | — | — | 0.66 | — | — | — | — | — | — | — | 63.40 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.97 | 41.88 | 43.34 | 6.83 | 2960.40 | — | 248.88 | — | 165.80 | 380.59 | 1323.66 | 3.74 | 10.51 | — | — | — | — | 2.63 | — | — | — |
| — | — | -82.6% | — | +1685.5% | — | -81.2% | — | +1477.7% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 25.13 | — | 35.99 | 9.84 | 9.37 | — | — | — | — | 12.79 | — | — | — | — | 17.89 | 6.10 | 3.22 | 3.18 | 4.05 | 2.69 | 2.68 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +341.6% | +127.0% | +20.0% | -74.2% | -82.5% | — | — | |
| P/FCF | — | — | — | 5.65 | — | — | — | 1.42 | — | 0.68 | — | — | — | — | — | — | 2.48 | — | — | — | 16.38 |
| — | — | — | +297.8% | — | — | — | — | — | — | — | — | — | — | — | — | -84.8% | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 47.53 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 0.37 | — | — | — | — | — | — | — | 48.19 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -137.5% | -70.6% | -422.8% | 71.1% | -51852.6% | 100.0% | -8935.2% | 22446.0% | 40.0% | 100.0% | -36034.1% | -1092.7% | 97.5% | — | — | — | — | 99.8% | — | — | — |
| — | -170.6% | +95.3% | -99.7% | -129618.2% | 0.0% | +75.2% | +2154.1% | -58.9% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1315.5% | -1582.5% | -1967.1% | -143.7% | -162340.8% | 18079.5% | -18016.7% | 8465.8% | -11228.7% | -32799.1% | -64743.9% | -286.1% | -839.6% | — | — | — | — | 3.8% | — | — | — |
| — | -108.8% | +89.1% | -101.7% | -1345.8% | +155.1% | +72.2% | +3059.5% | -1237.3% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1300.7% | -1590.4% | -1967.7% | -140.8% | -157505.1% | 18970.7% | -17219.1% | 8651.5% | -11279.4% | 57539.2% | -72622.6% | -279.8% | -829.9% | — | — | — | — | 4.1% | — | — | — |
| — | -108.4% | +88.6% | -101.6% | -1296.4% | -67.0% | +76.3% | +3192.6% | -1259.1% | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -471.4% | -3421.6% | -167.7% | -50.6% | -124.7% | — | — | — | -792.3% | 483.3% | — | — | — | -778.1% | -100.0% | -85.1% | -23.6% | 1.3% | -24.1% | -27.0% | -63.9% |
| — | — | — | — | +84.3% | — | — | — | — | +162.1% | — | — | — | -60162.1% | -314.6% | -215.1% | +63.0% | +100.8% | +96.5% | — | — | |
| ROA | -49.1% | -11.9% | -9.9% | -4.6% | -16.3% | -25.4% | -21.5% | -27.4% | -22.6% | 70.5% | -39.4% | -21.8% | -34.4% | -32.7% | -21.7% | -33.8% | -13.8% | 0.8% | -16.0% | -18.2% | -39.8% |
| — | +53.3% | +53.7% | +83.4% | +27.8% | -136.1% | +45.4% | -25.6% | +34.4% | +315.6% | -81.7% | +35.5% | -149.3% | -4073.4% | -35.5% | -85.6% | +65.3% | +101.1% | +80.3% | +83.6% | +57.4% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.93 | — | 2.20 | 0.93 | 1.03 | — | — | — | — | 0.57 | — | — | — | — | 0.08 | 0.04 | 0.02 | 0.03 | 0.04 | 0.01 | 0.01 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +102.1% | +530.0% | +83.8% | -45.4% | -78.6% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.95 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.14 | 0.99 | 1.03 | 1.14 | 1.18 | 0.34 | 0.56 | 0.85 | 1.14 | 1.43 | 0.56 | 0.86 | 0.85 | 0.90 | 1.21 | 1.36 | 2.17 | 3.03 | 2.92 | 3.44 | 3.03 |
| — | +187.1% | +83.8% | +33.8% | +3.7% | -75.9% | -0.9% | -0.3% | +33.4% | +58.5% | -53.6% | -37.1% | -60.8% | -70.3% | -58.4% | -60.5% | -28.4% | +29.4% | +85.6% | +277.8% | +245.8% | |
| Quick Ratio | 1.14 | 0.99 | 1.03 | 1.14 | 1.18 | 0.34 | 0.56 | 0.85 | 1.14 | 1.43 | 0.56 | 0.86 | 0.85 | 0.90 | 1.21 | 1.36 | 2.17 | 3.03 | 2.92 | 3.44 | 3.03 |
| — | +187.1% | +83.8% | +33.8% | +3.7% | -75.9% | -0.9% | -0.3% | +33.4% | +58.5% | -53.6% | -37.1% | -60.8% | -70.3% | -58.4% | -60.5% | -28.4% | +29.4% | +85.6% | +277.8% | +245.8% | |
| Interest Coverage | -15.29 | — | -14.05 | — | — | -13.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DARE stock.
Dare Bioscience, Inc.'s current P/E is -0.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Dare Bioscience, Inc.'s current operating margin is -1315.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Dare Bioscience, Inc.'s business trajectory between earnings reports.